British Biotech Pharmaceuticals Limited

British Bio-technology Limited

Pfizer Corporation

Isis Innovation Limited

G.d. Searle & Company

Richard Mark Edwards

Michael George Hunter

Keith Martyn Dawson

Lloyd George Czaplewski

Stewart Craig

Richard James Gilbert

Lindsay Jayne Bawden

Sandy Blackadder Primrose

John Martin Clements

David Graham Brown

Lars Michael Wood

Michael Berisford Comer

Julian F Burke

Anne L Cook

Joan M Forman

Anthony Fallon

Matthew John McCourt

A hybrid fusion protein comprising a first antigenic amino acid sequence fused to a second amino acid sequence substantially homologous to B2M or a fragment thereof.

Fusion proteins between antigenic amino acid sequences and beta-2-microglobulin

Stem cell inhibiting proteins

This invention relates to mutants of human RANTES (hRANTES) which, relative to the wild-type molecule, have a reduced tendency to aggregate into large multimeric complexes at physiological ionic strength and pH, and are less pro-inflammatory.

Disaggregated mutant human RANTES

Release and mobilization of haematopoietic cells

Proteinaceous molecules with stem cell inhibition activity are analogues of LD78 or MIP-1.alpha. which have mutations to prevent or reduce multimer formation beyond certain stages (for example a dodecamer). Aggregate formation is therefore inhibited, and the resulting low molecular weight monomers (or oligomers) have improved solution properties leading to enhanced productivity and greater therapeutic utility as stem cell protective agents, which are useful in tumour therapy.

Insulin-like Growth Factor II (IGF-II) analogues in which at least one of R37 and R38 is replaced with another amino acid residue, the most preferred being IGF-II R37Q R38Q, can readily be produced in E. coli, unlike natural IGF-II, which is cleaved on secretion. The analogues retain activity on the type I and type II IGF receptors but have lower affinity for the insulin receptor; they are therefore more specific in their action.

Growing community of inventors

Oxford, United Kingdom

Richard Mark Edwards